Mexico regulates medical AI like hardware: COFEPRIS requires three layers of evidence and ongoing monitoring

By Mexico Business News · November 5, 2026.

Mexico's Federal Commission for the Protection against Sanitary Risks (COFEPRIS) is consolidating its framework for artificial intelligence and software as a medical device (SaMD). According to Mexico Business News, the regulator is adapting its procedures to govern machine learning algorithms, diagnostic software and self-learning tools.

The foundation is the Class I to III risk-based classification system of the Pharmacopoeia of the United Mexican States (FEUM). According to the article, specific rules for autonomous algorithms are still being developed. Class II or III software, meaning software whose errors could cause immediate physiological harm or lead to irreversible surgical intervention, receives the same scrutiny as medical hardware.

Developers must demonstrate three layers of clinical evidence:

- **Valid clinical association:** show that the software's output correlates with the targeted disease or condition. - **Analytical validation:** verify that the algorithm is accurate, repeatable and reliable when processing complex data. - **Clinical validation:** prove that it produces safe and effective results in real diagnostic or therapeutic settings.

On top of this come software lifecycle controls under the IEC 62304 standard, change management, cybersecurity and technovigilance (tracking failures and adverse events of a product already on the market) in accordance with NOM-240-SSA1-2012. Good manufacturing practices are governed by NOM-241-SSA1-2025.

Oversight does not end with authorization. The article stresses that models can suffer drift (a loss of performance when real-world data differs from training data). That is why continuous monitoring and active reporting channels to the National Center for Pharmacovigilance and Technovigilance (CENAFyT) are required.

The piece also acknowledges institutional friction. According to the article itself, industry points to shortages of specialized staff at COFEPRIS, and the agency's leadership says it is working to reduce backlogs and to create a single digital window. Incomplete documentation can lengthen timelines even further.

**Our take.** Treating clinical AI with the same logic as an implant or imaging equipment is the right approach. An algorithm that helps diagnose is a medical product, and three-layer validation separates statistical correlation from proven clinical utility. That is exactly the distinction between proven capability and marketing promise that we champion at Zendoric.

The most valuable element is the post-market requirement. A model is not a static device: it changes with every update and degrades if the hospital, the equipment or the population differ from those in training. Requiring feedback to be built into the update cycle is, in our view, the piece that matters most in the long run. Broadly, other health regulators are moving in the same direction, so Mexico is not isolated.

The risk lies elsewhere. A rigorous framework with an understaffed regulator can become a bottleneck that delays useful tools or favors large companies, the only ones able to pay for consultants and flawless dossiers. That would penalize local startups. Moreover, the article itself admits that the rules for autonomous algorithms are not yet finalized, and that is where the quality of the framework will be decided.

In the short term, this means higher costs and longer timelines for anyone wanting to sell medical AI in Mexico. In the long term, it is the kind of trust infrastructure AI-assisted medicine needs to deliver on its promise: earlier and more accurate diagnoses, and more equitably distributed healthcare. Without that trust, the promise will not reach patients.